{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:15:36Z","timestamp":1790198136407,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","primary-care-diabetes.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Primary Care Diabetes"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.pcd.2020.10.002","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T11:14:34Z","timestamp":1603883674000},"page":"283-288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: A real-world experience"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5820-4178","authenticated-orcid":false,"given":"Andrea","family":"Tumminia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2289-6704","authenticated-orcid":false,"given":"Marco","family":"Graziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Vinciguerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lomonaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7941-5828","authenticated-orcid":false,"given":"Lucia","family":"Frittita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcd.2020.10.002_bib0005","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.2337\/dc12-1801","article-title":"Diabetes in older adults","volume":"35","author":"Kirkman","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2020.10.002_bib0010","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1046\/j.1532-5415.51.5s.1.x","article-title":"Guidelines for improving the care of the older person with diabetes mellitus","volume":"51","author":"Brown","year":"2003","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.pcd.2020.10.002_bib0015","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(16)00618-8","article-title":"Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants","volume":"387","author":"Collaboration","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pcd.2020.10.002_bib0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/jdi.12676","article-title":"Continuous glucose monitoring reveals hypoglycemia risk in elderly patients with type 2 diabetes mellitus","volume":"9","author":"Ishikawa","year":"2018","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.pcd.2020.10.002_bib0025","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.2337\/dc20-S012","article-title":"12. Older adults: standards of medical care in Diabetes-2020","volume":"43","author":"American Diabetes","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2020.10.002_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113306","article-title":"Type 2 diabetes mellitus and alzheimer\u2019s disease: role of insulin signalling and therapeutic implications","volume":"19","author":"Tumminia","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pcd.2020.10.002_bib0035","doi-asserted-by":"crossref","DOI":"10.3390\/nu12041019","article-title":"Influence of the Mediterranean and ketogenic diets on cognitive status and decline: a narrative review","volume":"12","author":"Vinciguerra","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.pcd.2020.10.002_bib0040","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the european association for the study of diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2020.10.002_bib0045","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/jdi.12214","article-title":"Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action","volume":"5","author":"Fujita","year":"2014","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.pcd.2020.10.002_bib0050","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.pcd.2020.10.002_bib0055","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s12325-017-0573-0","article-title":"Safety and tolerability of Empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials","volume":"34","author":"Kohler","year":"2017","journal-title":"Adv. Ther."},{"key":"10.1016\/j.pcd.2020.10.002_bib0060","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.pcd.2020.10.002_bib0065","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pcd.2020.10.002_bib0070","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pcd.2020.10.002_bib0075","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1472-6823-14-37","article-title":"Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies","volume":"14","author":"Sinclair","year":"2014","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.pcd.2020.10.002_bib0080","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/jgs.14028","article-title":"Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: a pooled analysis","volume":"64","author":"Sinclair","year":"2016","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.pcd.2020.10.002_bib0085","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s40266-016-0382-1","article-title":"Long-term safety of Dapagliflozin in older patients with type 2 diabetes mellitus: a pooled analysis of phase IIb\/III studies","volume":"33","author":"Fioretto","year":"2016","journal-title":"Drugs Aging"},{"key":"10.1016\/j.pcd.2020.10.002_bib0090","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2337\/dc19-1476","article-title":"Efficacy and safety of Dapagliflozin in the elderly: analysis from the DECLARE-TIMI 58 study","volume":"43","author":"Cahn","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2020.10.002_bib0095","unstructured":"Associazione Medici Diabetologi (AMD)-Societ\u00e0 Italiana di Diabetologia (SID). Standard Italiani per la Cura del Diabete Mellito 2018. 2020. Available from: http:\/\/www.standarditaliani.it\/ (Accessed 5 August)."},{"key":"10.1016\/j.pcd.2020.10.002_bib0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.pcd.2020.10.002_bib0105","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4140\/TCP.n.2014.335","article-title":"A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes","volume":"29","author":"Elmore","year":"2014","journal-title":"Consult. Pharm."},{"key":"10.1016\/j.pcd.2020.10.002_bib0110","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin. Pract."},{"key":"10.1016\/j.pcd.2020.10.002_bib0115","first-page":"709","article-title":"Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis, the lancet","volume":"5","author":"Birkeland","year":"2017","journal-title":"Diabetes Endocrinol."},{"key":"10.1016\/j.pcd.2020.10.002_bib0120","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/dom.13077","article-title":"Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study","volume":"20","author":"Persson","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.pcd.2020.10.002_bib0125","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.pcd.2020.10.002_bib0130","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1161\/CIRCULATIONAHA.117.031227","article-title":"Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (Evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world)","volume":"137","author":"Udell","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.pcd.2020.10.002_bib0135","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12933-019-0920-3","article-title":"Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs","volume":"18","author":"Schernthaner","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.pcd.2020.10.002_bib0140","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/03007995.2017.1392293","article-title":"Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan","volume":"34","author":"Goda","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.pcd.2020.10.002_bib0145","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s13300-019-0611-9","article-title":"A survey of the FDA\u2019s adverse event reporting system database concerning urogenital tract infections and sodium glucose Cotransporter-2 inhibitor use","volume":"10","author":"Shen","year":"2019","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.pcd.2020.10.002_bib0150","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/jdi.13125","article-title":"Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: a subanalysis of a post-marketing study (J-STEP\/EL Study)","volume":"11","author":"Kaku","year":"2020","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.pcd.2020.10.002_bib0155","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.2337\/dcS15-3006","article-title":"SGLT2 inhibitors and the diabetic kidney","volume":"39 Suppl 2","author":"Fioretto","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2020.10.002_bib0160","first-page":"27","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study, the lancet","volume":"8","author":"Heerspink","year":"2020","journal-title":"Diabetes Endocrinol."},{"key":"10.1016\/j.pcd.2020.10.002_bib0165","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1042\/CS20171298","article-title":"SGLT2 inhibition and kidney protection","volume":"132","author":"Nespoux","year":"2018","journal-title":"Clin. Sci."},{"key":"10.1016\/j.pcd.2020.10.002_bib0170","first-page":"S201","article-title":"Chronic kidney disease in diabetes","volume":"42 Suppl 1","author":"Diabetes Canada Clinical Practice Guidelines Expert","year":"2018","journal-title":"Can. J. Diabetes"}],"container-title":["Primary Care Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991820302874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991820302874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:59:40Z","timestamp":1761695980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1751991820302874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1751991820302874"],"URL":"https:\/\/doi.org\/10.1016\/j.pcd.2020.10.002","relation":{},"ISSN":["1751-9918"],"issn-type":[{"value":"1751-9918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: A real-world experience","name":"articletitle","label":"Article Title"},{"value":"Primary Care Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcd.2020.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}